PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsMucopolysaccharidosis iv
MeSH D009085 - mucopolysaccharidosis iv
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009083:Mucopolysaccharidoses
0 Companies
0 Drugs
Success rate
D009085: 
Mucopolysaccharidosis iv
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BioMarin PharmaceuticalElosulfase alfa Vimizim  2014-02-14 $724.294 M Q4/23-Q3/24 
Clinical Trials
Historical Success Rate
Phase 1
50%
1/2
Phase 2
50%
1/2
Phase 3
75%
3/4
Approved: 2Overall Success rate: 19%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
BioMarin Pharmaceutical
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use